scholarly article | Q13442814 |
P50 | author | Matthias Voßen | Q56389312 |
Sandra Pferschy | Q56491010 | ||
Daniela Knafl | Q88470992 | ||
P2093 | author name string | W Jäger | |
M Unger | |||
A Maier-Salamon | |||
F Thalhammer | |||
M Haidinger | |||
R Lemmerer | |||
W Lamm | |||
P2860 | cites work | Invasive candidiasis as a cause of sepsis in the critically ill patient | Q22305429 |
Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits | Q34108880 | ||
Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America | Q34505582 | ||
Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia | Q34933267 | ||
In vitro echinocandin susceptibility of Aspergillus isolates from patients enrolled in the Transplant-Associated Infection Surveillance Network | Q35139558 | ||
Doripenem Treatment during Continuous Renal Replacement Therapy | Q36644597 | ||
Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy. | Q37036404 | ||
Clinical pharmacokinetics of systemically administered antimycotics. | Q37239121 | ||
Effects of renal replacement therapy on antimicrobial therapy. | Q38040475 | ||
Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA Score for In-Hospital Mortality Among Adults With Suspected Infection Admitted to the Intensive Care Unit | Q39004033 | ||
Multiple-dose pharmacokinetics of anidulafungin during continuous venovenous haemofiltration | Q39169777 | ||
The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro | Q39652699 | ||
Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation | Q40546653 | ||
Invasive candidiasis in intensive care units in China: Risk factors and prognoses of Candida albicans and non-albicans Candida infections | Q40828130 | ||
Optimal prophylactic dosage and disposition of micafungin in living donor liver recipients | Q42163324 | ||
Combination antifungal therapy for invasive aspergillosis: a randomized trial. | Q44442690 | ||
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). | Q47643506 | ||
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. | Q47643534 | ||
The Effect of Time to Antifungal Therapy on Mortality in Candidemia Associated Septic Shock | Q57779776 | ||
Pharmacokinetics of Antifungal Agent Micafungin in Critically Ill Patients Receiving Continuous Hemodialysis Filtration | Q59153121 | ||
Micafungin pharmacokinetic/pharmacodynamic adequacy for the treatment of invasive candidiasis in critically ill patients on continuous venovenous haemofiltration | Q61777104 | ||
Time to Initiation of Fluconazole Therapy Impacts Mortality in Patients with Candidemia: A Multi‐Institutional Study | Q61833672 | ||
Elimination of piperacillin and tazobactam by renal replacement therapies with AN69 and polysulfone hemofilters: evaluation of the sieving coefficient | Q83215288 | ||
Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational study | Q83485629 | ||
Pharmacokinetics/pharmacodynamics of micafungin in a surgical critically ill patient during extracorporeal carbon dioxide removal and continuous renal replacement therapy | Q85417874 | ||
Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH | Q86441854 | ||
Anidulafungin dosing in critically ill patients with continuous venovenous haemodiafiltration | Q87173846 | ||
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P577 | publication date | 2017-06-05 | |
P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
P1476 | title | Micafungin Plasma Levels Are Not Affected by Continuous Renal Replacement Therapy: Experience in Critically Ill Patients | |
P478 | volume | 61 |
Q92613683 | Antifungal Drugs Influence Neutrophil Effector Functions |
Q52807819 | Elimination of Doripenem during Dialysis and Pharmacokinetic Evaluation of Posthemodialysis Dosing for Patients Undergoing Intermittent Renal Replacement Therapy. |
Q64926124 | Ex vivo Rezafungin Adsorption and Clearance During Continuous Renal Replacement Therapy. |
Q58079557 | Optimizing micafungin dosing in critically ill patients: what about extracorporeal therapies? |
Q47876785 | Pharmacokinetic Properties of Micafungin in Critically Ill Patients Diagnosed with Invasive Candidiasis. |
Q91525647 | Pharmacokinetics of Micafungin in Critically Ill Patients |
Search more.